Theralase Technologi (TLTFF) 0.2414 $TLTFF Theralase

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Theralase Technologi (TLTFF) 0.2414 $TLTFF

Theralase Completes Clinical Protocol
Filing Services Canada XHTML - Fri Sep 11, 6:04AM CDT

TLT.VN: 0.305 (+0.005)

Theralase Successfully Completes GLP Toxicology Analysis of Lead Drug
Filing Services Canada XHTML - Thu Sep 10, 6:05AM CDT

TLT.VN: 0.305 (+0.005)

Theralase Research Demonstrates Lead Drug Also Effective for Muscle Invasive Bladder Cancer
Filing Services Canada XHTML - Wed Sep 09, 6:01AM CDT

TLT.VN: 0.305 (+0.005)

Theralase Completes GMP Manufacture of Lead Drug
Filing Services Canada XHTML - Tue Sep 08, 6:00AM CDT

TLT.VN: 0.305 (+0.005)

Theralase Demonstrates Stability of Lead Drug
Filing Services Canada XHTML - Fri Sep 04, 6:00AM CDT

TLT.VN: 0.305 (+0.005)

Theralase Expands Photo Dynamic Compound Pipeline
Filing Services Canada XHTML - Thu Sep 03, 6:03AM CDT

TLT.VN: 0.305 (+0.005)

Theralase Releases 2Q2015 Financials
Filing Services Canada XHTML - Fri Aug 28, 3:03PM CDT

TLT.VN: 0.305 (+0.005)

Theralase Provides Corporate Update
Filing Services Canada - Mon Aug 17, 6:04AM CDT
Theralase Provides Corporate Update Toronto, Ontario (FSCwire) - Theralase Technologies Inc. (Theralase or the Company) (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has provided a comprehensive corporate update on a recent radio program entitled The Korelin Economics Report. These highlights include: Status of regulatory approval for next generation therapeutic laser Status of sales and marketing team for product launch Revenue expectations post product launch Full interview available here: http://www.kereport.com/2015/08/14/roger-whit...theralase/ (http://www.kereport.com/2015/08/14/roger-white-update-tlc2000-newest-product-theralase/) Roger Dumoulin-White, President and CEO, Theralase stated, Theralase is completing the final steps for commercialization of our next generation therapeutic laser as we await Canadian regulatory approval. Post launch, the Company will be in a position to demonstrate the enhanced efficacy that this next generation technology will bring to the worldwide pain market. About Theralase Technologies Inc. Theralase Technologies Inc. (Theralase(R)) (TSXV: TLT) (TLTFF: OTC) in its Therapeutic Laser Technology Division designs, manufactures and markets patented super-pulsed laser technology indicated for the: elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numerous nerve, muscle and joint conditions. Theralases Photo Dynamic Therapy Division researches and develops specially designed molecules called Photo Dynamic Compounds, which are able to localize to cancer cells and then when laser light activated, effectively destroy them. Additional information is available at www.theralase.com (http://www.theralase.com/) and www.sedar.com (http://www.sedar.com/) . Theralase Technologies Inc. was recognized as a TSX Venture 50(R) company in 2015. TSX Venture 50 is a trademark of TSX Inc. and is used under license. This press release contains forward-looking statements, which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release. For More Information: Michael Borovec Director of Investor Relations 1.866.THE.LASE (843-5273) ext. 222 416.699.LASE (5273) ext. 222 mborovec@theralase.com (mailto:mborovec@theralase.com) www.theralase.com (http://www.theralase.com) To view this press release as a PDF file, click onto the following link: http://fscwire.com/sites/default/files/news_r...172015.pdf Source: Theralase Technologies Inc. (TSX Venture:TLT, OTC Pink:TLTFF) http://theralase.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
TLT.VN: 0.305 (+0.005)

Theralase Achieves 98% Destruction of Bladder Cancer
Filing Services Canada XHTML - Wed Jul 22, 6:15AM CDT

TLT.VN: 0.305 (+0.005)

Theralase Appoints Experienced Sales and Marketing Team to Launch Next Generation Therapeutic Laser
ACCESSWIRE - Fri Jul 17, 8:52AM CDT
TORONTO, ON / ACCESSWIRE / July 17, 2015 / Theralase Technologies Inc. ("Theralase" or the "Company" (TLT:TSXV) (TLTFF:OTC), a leading biotechnology manufacturer focused on commercializing medical technologies to eliminate pain and destroy cancer, announced today that it has appointed an experienced sales and marketing team to launch its next generation therapeutic laser.
TLT.VN: 0.305 (+0.005)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

FIU's PPRIM Device: A New Hope Against Preterm Births

Updated Category News Views 54

Engineering a Leap in Prenatal Care Talk about flipping the script on prenatal diagnostics. A team from Florida International University (FIU) thinks they've got just the thing to spot early risks of preterm births with a device called PPRIM. It's the brainchild of some sharp minds, including FIU doctoral students Jenny Pei and Amanda Sanchez, and it's come out of FIU's...

Continue Reading
Lower Salford Township Upgrades AED Access with Avive

Updated Category News Views 54

Community Safety Takes Center Stage When it comes to community safety, the urgency can't be overstated, especially in a place like Lower Salford Township, Pennsylvania. This small township with around 16,000 residents has managed to pull off quite the feat in enhancing its emergency response capabilities by deploying 16 Avive Connect AED® devices throughout its police...

Continue Reading
Protalix Posts Strong Gains, Eyes Future Milestones

Updated Category News Views 87

Big Numbers and Bigger Ambitions Protalix BioTherapeutics has come out strong in their third quarter of 2026, showcasing some staggering numbers and laying out ambitious plans for the future. They've managed to pump their revenues up to a cool $75.6 million year-to-date, a leap from $43.6 million in the same period last year. You don't need a crystal ball to see them...

Continue Reading
Cell Counting Market Growth: USD 17.71 Billion by 2031

Updated Category News Views 199

The Cell Counting Surge: Money Talks in Science You can't deny it when the numbers speak—a jump from USD 12.39 billion to USD 17.71 billion by 2031 in the cell counting market means something ain't business as usual. That's a robust 7.40% CAGR folks; it's a field being bombarded with innovation. The spark? Automated and advanced cell analysis technology taking the...

Continue Reading
Samsung Display's Cybersecurity Milestone in Auto Sector

Updated Category News Views 73

Who would've thought we'd be tossing around terms like 'ISO certification' and 'cybersecurity' in the auto sector? Well, welcome to your new reality in 2026, where safeguarding our data is as critical as keeping engines running smoothly. Samsung Display just snagged an ISO/SAE 21434 certification along with an ENX Vehicle Cyber Security label. That's no small...

Continue Reading
McEwen Faces Investigation Amid Declining Production

Updated Category News Views 42

MUX Investors on Alert as Legal Stakes Rise The gold mining world isn't exactly flooded with excitement these days, and McEwen Inc.'s (NYSE: MUX) latest dealings ain't doing much to brighten up the scenery. When their third-quarter gold output took a nosedive—a 23% drop to be exact—it caught more eyes than a bull market will. Production Guidance in Question Now,...

Continue Reading
Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

Updated Category News Views 89

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Continue Reading
Munters Updates Financial Targets Amid Growth Plans

Updated Category News Views 23

Munters' Bold New Targets and Strategic Moves Ever feel like you're on a constant treadmill chasing numbers? Munters Group knows the feeling. Over in Stockholm, they've just laid out fresh strategies at their Capital Markets Day—not just any pie-in-the-sky type goals, but heavy hitters that are setting the tone for their future. CEO Stefan Aspman is all geared up,...

Continue Reading
Envista's $430M Senior Notes: A Market Move Decoded

Updated Category News Views 114

Envista on the Move with $430M Notes Ever feel like the market's a bit like a rollercoaster with no brakes? That's kind of where we're at with Envista Holdings Corporation (NYSE: NVST) rolling out this new financial play. They just priced a hefty $430 million in Senior Notes at a solid 6.250% due 2033. In terms of the investment world, that's a pretty big splash. The...

Continue Reading
BD Sets Stage for Investor Day in December 2026

Updated Category News Views 48

BD's Investor Day: A Peek into the Future Say what you will about investor meets, but BD (Becton, Dickinson and Company) throwing its shindig on December 10, 2026, could be a highlight on the calendar if you're eyeing the medical technology sector. Scheduled in New York, this event is gearing up to be a canvas for BD's higher-ups to sketch out their roadmap. If you’re...

Continue Reading

Top 5 Most Recently Viewed Articles

Mack-Cali Realty Corp's Stock Hits New Peak Amid Market Shifts

Updated Category News Views 101

Mack-Cali Realty Corp's Impressive Stock Performance During a time filled with market uncertainties and fluctuating trends, Mack-Cali Realty Corp's stock (NYSE: VRE) has remarkably risen to a 52-week high, reaching $18.1. This achievement reflects the company's strength in the real estate sector. Over the past year, VRE has grown modestly by 1.87%, indicating a consistent...

Continue Reading
Arctera’s Ascendancy as Leader in Digital Communications Governance

Updated Category News Views 245

Arctera Declared a Leader in Digital Communications Governance Arctera, previously part of Veritas Technologies, has made headlines by securing its position as a Leader in the Gartner Magic Quadrant for Digital Communications Governance and Archiving Solutions. This recognition reflects the company's commitment to enhancing data governance in an increasingly complex...

Continue Reading
NAB Show New York 2025: A Hub for Innovators and Creators

Updated Category News Views 200

Experience the NAB Show New York 2025 The 2025 NAB Show New York begins tomorrow at the Javits Center, and it's set to be a remarkable gathering for creators, innovators, and media professionals. With more than 12,000 registered attendees from around the globe, this event promises to cultivate exciting conversations and groundbreaking ideas across diverse media sectors....

Continue Reading
Brian Marynowitz Receives 2024 Emerging Leader Award

Updated Category News Views 160

Brian Marynowitz Honored as an Emerging Leader LBMC, a prominent accounting and business consulting firm, is thrilled to announce that Brian Marynowitz has been awarded the 2024 M&A Advisor’s 15th Annual Emerging Leaders Award. This prestigious accolade highlights young professionals who are making remarkable contributions to the mergers and acquisitions (M&A) field and...

Continue Reading
The Little Gym Gains Prestige in Entrepreneur’s Franchise Rankings

Updated Category News Views 138

The Little Gym Recognized for Franchise Excellence The Little Gym, renowned for its child enrichment and development programs, recently achieved the impressive milestone of securing the No. 125 spot on Entrepreneur's prestigious Franchise 500 list. This acknowledgment is a testament to the brand's tremendous efforts following a year marked by impressive growth and...

Continue Reading